In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade.
AstraZeneca announced in late May it plans to raise revenues from $45.8 billion in 2023 to $80.billion in 2030, as well as release 20 new drugs by then."Biology is complicated, and we're never sure of anything. But we have a great level of confidence we can get there, and I think this target forces us to think creatively and be ambitious and stretch," Soriot said."But we have a large portfolio of existing products, several blockbusters...
The company recently released promising results about several of its cancer drugs at the American Society of Clinical Oncology's annual meeting, including ones for lung and breast cancers.Cramer's Lightning Round: SoundHound is a sell "Science has exploded in the last ten, fifteen years, and what you see happen at the ASCO gives you hope that the day when cancer can be cured is not that far away," he said."Either cured or turned to a chronic condition."news
ایران آخرین اخبار, ایران سرفصلها
Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.
منبع: NBCLA - 🏆 319. / 59 ادامه مطلب »